Steroid Injection Approach for Elderly Shoulder with Glenohumeral Osteoarthritis
While corticosteroid injections are widely used in clinical practice for glenohumeral osteoarthritis, the evidence does not support or refute their efficacy, and you should consider viscosupplementation (hyaluronic acid) as a potentially superior alternative, particularly for sustained benefit beyond 6 months. 1
Evidence-Based Recommendations
Primary Injection Options
The AAOS guidelines explicitly state they are "unable to recommend for or against the use of injectable corticosteroids in the treatment of patients with GH OA" (Grade I recommendation, Level V evidence). 1 This reflects the complete absence of quality evidence supporting corticosteroid injections specifically for glenohumeral osteoarthritis, despite their widespread use.
In contrast, viscosupplementation (hyaluronic acid) receives a Grade C recommendation as "an option when treating patients with GH OA." 1 The most recent evidence from 2026 demonstrates that hyaluronic acid infiltration is more effective than corticosteroid infiltration for pain and function outcomes, particularly after 6 months post-injection, with best results in mild to moderate cases. 2
If You Choose Corticosteroid Injection
Despite limited evidence, if you proceed with corticosteroid injection based on clinical judgment:
Timing considerations:
- Avoid injection within 3 months of planned arthroplasty - this significantly increases infection risk (RR 2.30, p=0.02). 3
- Injections given 3-12 months before surgery do not increase infection risk. 3
Expected outcomes:
- Provides clinically significant pain relief for approximately 4 months maximum. 4
- Effect sizes decrease rapidly at follow-up (1.08 at 6 weeks, 0.43 at 12 weeks, 0.19 at 26 weeks). 5
- Patients with more severe baseline dysfunction (worse Oxford Shoulder Score) experience greater symptomatic relief than those with milder dysfunction. 4
- Receiving at least one glenohumeral corticosteroid injection decreases the risk of failing nonoperative treatment (HR 0.16, p=0.012). 6
Technical approach:
- The AAOS guidelines note that evidence does not distinguish between injections performed with or without fluoroscopic, ultrasound, or CT guidance. 1
- However, EULAR 2021 guidelines state that image guidance "may be used to improve accuracy." 7
- Use aseptic technique always. 7
- Offer local anesthetic, explaining pros and cons. 7
Patient counseling:
- Diabetic patients: Warn about transient hyperglycemia risk from first to third day post-injection; advise glucose monitoring. 7
- Activity modification: Avoid overuse of injected joint for 24 hours, but do not immobilize. 7
- Repeated injections: The decision to reinject should consider benefits from previous injections and individual factors. 7
Clinical Algorithm
Assess disease severity (radiographic and functional)
If corticosteroid chosen:
If hyaluronic acid chosen:
Critical Pitfalls
- Do not assume corticosteroid injections are evidence-based for glenohumeral OA - they lack supporting data despite common use. 1
- Do not inject within 3 months of planned arthroplasty - infection risk triples. 3
- Do not expect prolonged benefit from corticosteroids - efficacy drops dramatically after 3-4 months. 4, 5
- Do not overlook hyaluronic acid - it has better evidence and longer-lasting effects than corticosteroids. 2
The fundamental issue is that only 30% of patients with glenohumeral OA who choose nonoperative treatment achieve clinically meaningful improvements, yet less than 25% proceed to surgery at short-term follow-up. 6 This suggests that while injections may provide temporary relief, they rarely produce transformative outcomes in this population.